PORTEC-3试验中放疗技术与治疗相关毒性:三维适形与调强放疗比较
PORTEC-3随机试验高危子宫内膜癌患者中,559例接受3DCRT、99例接受IMRT,中位随访74.6个月。IMRT组治疗期间≥3级不良事件更少(趋势),随访期≥2级腹泻和血液学不良事件显著更低。
核心结论
- IMRT较3DCRT减少治疗期间≥3级不良事件,并显著降低随访期≥2级腹泻和血液学不良事件。
- IMRT组患者报告排便急迫和腹部绞痛有减少趋势。
研究设计与样本
- PORTEC-3随机试验中高危子宫内膜癌患者的不良事件和生活质量分析。
- 658例可评估患者中559例接受3DCRT、99例接受IMRT,中位随访74.6个月。
- 不良事件按CTCAE v3.0分级,生活质量采用EORTC QLQ-C30、CX24和OV28问卷评估。
关键数值与推荐
- 不良事件分级采用CTCAE v3.0。
- 生活质量问卷为EORTC QLQ-C30、CX24和OV28。
- 生活质量分析将评分1-2分(完全无/有一点)与3-4分(相当多/非常多)合并比较。
临床怎么用
- 在高危子宫内膜癌放疗中,IMRT可减少治疗期间严重不良事件及随访期腹泻和血液学毒性。
- IMRT可能改善患者报告的排便急迫和腹部绞痛,支持其作为减少肠道毒性的技术选择。
局限性
- IMRT组样本量(99例)明显少于3DCRT组(559例)。
- 患者报告腹泻和腹部绞痛的组间差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy techniques have developed from 3-dimensional conformal radiation therapy (3DCRT) to intensity modulated radiation therapy (IMRT), with better sparing of the surrounding normal tissues. The current analysis aimed to investigate whether IMRT, compared to 3DCRT, resulted in fewer adverse events (AEs) and patient-reported symptoms in the randomized PORTEC-3 trial for high-risk endometrial cancer. METHODS AND MATERIALS: Data on AEs and patient-reported quality of life (QoL) of the PORTEC-3 trial were available for analysis. Physician-reported AEs were graded using Common Terminology Criteria for Adverse Events v3.0. QoL was assessed by the European Organisation for Research and Treatment of Cancer QLQC30, CX24, and OV28 questionnaires. Data were compared between 3DCRT and IMRT. A P value of ≤ .01 was considered statistically significant due to the risk of multiple testing. For QoL, combined scores 1 to 2 ("not at all" and "a little") versus 3 to 4 ("quite a bit" and "very much") were compared between the techniques. RESULTS: Of 658 evaluable patients, 559 received 3DCRT and 99 IMRT. Median follow-up was 74.6 months. During treatment no significant differences were observed, with a trend for more grade ≥3 AEs, mostly hematologic and gastrointestinal, after 3DCRT (37.7% vs 26.3%, P = .03). During follow-up, 15.4% (vs 4%) had grade ≥2 diarrhea, and 26.1% (vs 13.1%) had grade ≥2 hematologic AEs after 3DCRT (vs IMRT) (both P < .01). Among 574 (87%) patients evaluable for QoL, 494 received 3DCRT and 80 IMRT. During treatment, 37.5% (vs 28.6%) reported diarrhea after 3DCRT (vs IMRT) (P = .125); 22.1% (versus 10.0%) bowel urgency (P = 0039), and 18.2% and 8.6% abdominal cramps (P = .058). Other QoL scores showed no differences. CONCLUSIONS: IMRT resulted in fewer grade ≥3 AEs during treatment and significantly lower rates of grade ≥2 diarrhea and hematologic AEs during follow-up. Trends toward fewer patient-reported bowel urgency and abdominal cramps were observed after IMRT compared to 3DCRT.
引用
- Wortman BG, Post CCB, Powell ME, et al. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 34610387. doi:10.1016/j.ijrobp.2021.09.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。